We focused on the effect of paclitaxel on the metabolism of gemci

We focused on the effect of paclitaxel on the metabolism of gemcitabine at this time based on previous data that indicate dCK activity corresponds to the sensitivity of murine tumors and human tumor xenografts to gemcitabine and CDA activity corresponds to myelosuppression in children [8, 12]. We selected three solid tumor cell lines representing the most common histologies in patients diagnosed with advanced NSCLC; these immortalized cell lines were acquired from patients with advanced disease (H460, squamous cell carcinoma; H520, large cell carcinoma; and H838, adenocarcinoma). The

IWP-2 datasheet multiple drug effect analysis indicates this interaction is largely independent of culture conditions or sequence; but a sequence dependent effect was noted regarding the fraction of affected cells with the gemcitabine-paclitaxel sequence favored in two of the three cell lines (H460, H838). Our results for

the H460 cells compare well with a previous report in which the CI for sequential paclitaxel-gemcitabine and gemcitabine-paclitaxel was reported Selleck SAR302503 for similar exposure [20]. Although our data supports administering gemcitabine before paclitaxel based on the fraction affected, the percentage of apoptotic cells largely favors paclitaxel before gemcitabine consistent with the current administration of this combination to patients with advanced breast, lung or ovarian cancers. Dr. Kroep similarly concluded that sequential paclitaxel-gemcitabine was favored based on an increase in apoptosis compared to the reverse sequence [20]. As anticipated, paclitaxel increased

the number of G2/M cells and gemcitabine increased the number of G0/G1 or S cells. A relationship between cell cycle distribution and the CI was not observed. Only one other study explored Astemizole possible effects of paclitaxel on dCK, but no other studies have described the effects of paclitaxel on CDA [20]. Kroep et al[20] reported that paclitaxel increased the accumulation of the triphosphorylated metabolite in H460 cells, but that dCK activity was not changed. Our findings indicate that paclitaxel increased dCK activity in all three cells lines including H460 cells and that the changes were only statistically significantly higher in the H520 cells. However, the mRNA levels were significantly reduced in two cells lines, H460 and H520, with relatively substantial decreases in protein. It is unclear why the reported outcomes are different in these studies, but the differences may be dependent on allosteric Entinostat datasheet regulation governed by differences in substrate concentrations of dCTP.

Comments are closed.